Navigation Links
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
Date:6/8/2009

n focal dystonia was analyzed on the pooled data from 2 pivotal clinical trials in blepharospasm and cervical dystonia (343 NT 201 patients; 340 BTXCo* patients) and 1 post-stroke spasticity trial (73 NT 201 patients and 75 placebo patients). For the safety analyses, 6 clinical trials (blepharospasm, cervical dystonia, and upper limb spasticity) have been included (n=539 NT 201, n=442 BTXCo and n=75 placebo subjects). For the post-launch evaluation spontaneously reported adverse events were analyzed.

Results

In the randomized, active-controlled, double-blind studies in focal dystonia NT 201 and one other Botulinum toxin (BTXCo) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the NT 201 and BTXCo. Onset, waning, and duration of effect were comparable. These findings have been confirmed by the Physician´s Global Impression of Efficacy: 70.6% of BTXCo patients and 71.8% of the NT 201 patients were rated as "good" or "very good." Additionally, in the placebo-controlled spasticity trial 62% of the caregivers rated the efficacy as good or very good compared to placebo (33%). 26.7% of patients in the NT 201 group, 26.0% in the BTXCo group, and 22.7% in the placebo group reported an adverse event. There were no clinically relevant differences between the two active treatment groups in the focal dystonia trials and between NT 201 and placebo in the post-stroke spasticity trial concerning safety aspects. All adverse reactions were either already known and/or were considered by the physician unlikely to be related to NT 201. More than 67,000 patients have been treated so far and no new safety concerns have been reported.

Second Study - Title

NT201 (Xeomin(R); botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies authored by Barnes, M., Schnitzler, A., Amaral e Silva, A., Aquilar, M., Lehner
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
10. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
11. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Eisai Inc. announced today that regulatory applications ... , European Union and Japan ... eribulin, for the treatment of patients with inoperable soft ... advanced or metastatic disease. These regulatory ... Phase 3 clinical trial (Study 309), which met its ...
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional ... variety of nutritional and wellness products, announced the addition of Vincent Aquilino to ... therapy, active isolated stretching and the prevention and rehabilitation of injuries, has spent ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... the growing number of individuals who remain undiagnosed, treatment options for patients are ... away from traditional CPAP therapy due to its overall lack of comfort and ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... Obama’s call to action by asking community members to contribute to the College’s “My ... “Helping more of our young people stay on track. Providing the support they need ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... transmission did not cause infection among caregivers in study ... study estimates that more than 12 percent of people ... infected with MRSA, or methicillin-resistant Staphylococcus aureus, and ... to others in their household. , The researchers, Dr. ...
... the cheerful, study finds , MONDAY, Aug. 10 (HealthDay News) ... more likely to develop heart trouble than those with a ... comes from the Women,s Health Initiative, which has tracked more ... , "In addition to looking at hormones and their effect ...
... , , WASHINGTON, Aug. 10 ... is an immigrant (legal or illegal) or the U.S.-born child (under ... one-fourth of those on Medicaid. While there has been some ... insurance plans, the enormous impact of immigration, both legal and illegal, ...
... , ROLLING HILLS ESTATES, Calif., ... Device Connectivity Conference & Exhibition, organized by The Center for ... at the Joseph B. Martin Conference Center at Harvard Medical ... an outstanding agenda with nationally recognized experts from academia, provider ...
... , , FLORENCE, Italy, Aug. 10 ... a North American subsidiary of its DEKA division. Based in San ... bringing a selected range of medical and aesthetic devices under the ... SmartXide DOT. , , The new management team ...
... , LAKEWOOD, N.J., Aug. 10 PLUS ... announced today that it has expanded its executive team with the addition ... M.D. to chief medical officer and Mark Machulcz to executive vice president ... Mr. Machulcz bring more than 30 years of combined anatomic pathology experience ...
Cached Medicine News:Health News:Staph Infection May Follow People Home From Hospital 2Health News:Optimism Good for Heart and Longevity 2Health News:Optimism Good for Heart and Longevity 3Health News:Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems 2Health News:El.En. Group Establishes New Subsidiary, DEKA Medical, Inc. and Appoints Management Team 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: